RANK Ligand: A Key Role in Cancer-Induced Bone Destruction?

European Urology, Supplements

Volumn 8, Issue 11, 2009, Pages 823-828

  Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bone; Bone metastases; Cancer; Cancer treatment induced bone loss; Denosumab; OPG; Osteoprotegerin; RANK; RANK Ligand

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE DESTRUCTION; BONE METABOLISM; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG INHIBITION; HUMAN; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; TUMOR GROWTH;

EID: 72049101193     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.09.001     Document Type: Review

References (36)

1. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12 (2006) 6243-9s
2. Rubens R.D., and Coleman R.E. Bone metastases. In: Abeloff M.D., Armitage J.O., Lichter A.S., et al. (Eds). Clinical Oncology (1995), Churchill Livingstone, New York, NY 643-665
3. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
4. Selvaggi G., and Scagliotti G.V. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 56 (2005) 365-378
5. Israeli R.S. Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol 10 (2008) 99-110
6. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
7. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
8. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
9. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
10. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
11. Fuller K., Wong B., Fox S., Choi Y., and Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188 (1998) 997-1001
12. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 (1998) 3597-3602
13. Lloyd S.A., Yuan Y.Y., Kostenuik P.J., et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int 82 (2008) 361-372
14. Galli C., Zella L.A., Fretz J.A., et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappa B ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149 (2008) 146-153
15. Udagawa N., Takahashi N., Yasuda H., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 (2000) 3478-3484
16. Tat S.K., Padrines M., Theoleyre S., et al. OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 39 (2006) 706-715
17. O'Brien E.A., Williams J.H., and Marshall M.J. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274 (2000) 281-290
18. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157 (2000) 435-448
19. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
20. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
21. Guise T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12 (2006) 6213-6s
22. Roodman G.D., and Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34 (2008) 92-101
23. Aoki J., Yamamoto I., Hino M., et al. Osteoclast-mediated osteolysis in bone metastasis from renal cell carcinoma. Cancer 62 (1988) 98-104
24. Clarke N.W., McClure J., and George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68 (1991) 74-80
25. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655-1664
26. Thomas R.J., Guise T.A., Yin J.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140 (1999) 4451-4458
27. Sanders J.L., Chattopadhyay N., Kifor O., Yamaguchi T., Butters R.R., and Brown E.M. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141 (2000) 4357-4364
28. Doumouchtsis K.K., Kostakis A.I., Doumouchtsis S.K., et al. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int 12 (2008) 100-107
29. Brown J.M., Corey E., Lee Z.D., et al. Osteoprotegerin and RANK Ligand expression in prostate cancer. Urology 57 (2001) 611-616
30. Jung K., Stephan C., Semjonow A., Lein M., Schnorr D., and Loening S.A. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170 (2003) 2302-2305
31. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783-791
32. Corey E., Brown L.G., Kiefer J.A., et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65 (2005) 1710-1718
33. Yonou H., Kanomata N., Goya M., et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63 (2003) 2096-2102
34. Kiefer J.A., Vessella R.L., Quinn J.E., et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 21 (2004) 381-387
35. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., and Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61 (2001) 4432-4436
36. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004) 1059-1066